Intraocular Lens Postmarket Surveillance Supported By Ophthalmic Panelists
This article was originally published in The Gray Sheet
Executive Summary
Postmarket surveillance for phakic intraocular lenses (IOLs) is largely favored by members of FDA's Ophthalmic Devices Panel, although recommended duration could vary depending on risk
You may also be interested in...
Separate Phakic IOL Trials Recommended For Young, Old Patients
Refractive implant manufacturers pursuing claims for device implantation in phakic eyes - those with a natural lens - should conduct separate studies on younger and older patient populations to examine the risk of cataractogenesis, FDA's Ophthalmic Devices Advisory Panel recommended at a May 12 meeting.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.